Persistent ill health after acute COVID-19—referred to as long COVID, the post-acute COVID-19
syndrome, or the post-COVID-19 condition—has emerged as a major concern. We …

Systemic corticosteroid use to manage uncontrolled asthma and its associated healthcare
burden may account for important health-related adverse effects. We conducted a systematic …

Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms,
exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …

Background Many patients with severe asthma rely on oral glucocorticoids to manage their
disease. We investigated whether benralizumab, a monoclonal antibody directed against the …

Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …

Background— The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …

Background Clinical trials have shown treatment benefits of dupilumab in patients with
uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and …

Although asthma is very common, affecting 5–10% of the population, the diagnosis of
asthma in adults remains a challenge in the real world, which results in both over- and under-…

Background Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal
antibody that has been shown to safely reduce exacerbations and improve lung function for …